Log In
BCIQ
Print this Print this
 

Oratecan

  Manage Alerts
Collapse Summary General Information
Company Hanmi Pharmaceutical Co. Ltd.
DescriptionOral irinotecan plus P glycoprotein inhibitor (HM30181A; MDR1)
Molecular Target ATP-binding cassette sub-family B member 1 (ABCB1) (MDR1) (PGP) (CD243)
Mechanism of ActionP glycoprotein (MDR) inhibitor
Therapeutic ModalitySmall molecule

 Product Details
Disease CategoryStandard IndicationIndication DetailsPartnersMilestonesLatest Stage of DevelopmentRegulatory Designation
 Archive Items are loading loading
Collapse Summary Deals Information
Total Number of DealsTotal Deal ValueTotal Upfront CashTotal Milestone Payments

2

0

0

0


 Deals Details
DateCompanies InvolvedDeal HeadlineTotal Deal ValueTotal Upfront CashTotal Milestone

02/17/2014

Undisclosed

Undisclosed

Undisclosed

05/13/2013

Undisclosed

Undisclosed

Undisclosed

Get a free BioCentury trial today